Anavex Life Sciences Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVXL Nasdaq 2836 www.anavex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anavex Life Sciences Corp.

Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting - Sep 24th, 2026 8:00 am
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences - Sep 18th, 2026 7:48 am
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change - Sep 17th, 2026 10:17 am
PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance - Sep 14th, 2026 5:30 pm
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees - Sep 14th, 2026 6:30 am
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign - Sep 10th, 2026 12:45 pm
PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL) - Sep 9th, 2026 7:53 am
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET - Sep 8th, 2026 6:00 am
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company - Sep 3rd, 2026 3:46 pm
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement - Sep 2nd, 2026 2:00 pm
PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting - Sep 1st, 2026 3:35 pm
Sector Update: Healthcare Stocks Advance Late Afternoon - Aug 25th, 2026 1:57 pm
Anavex Life Sciences Advances Alzheimer’s Phase 3 Planning as Cash Runway Extends Into Fiscal 2028 - Aug 25th, 2026 8:46 am
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update - Aug 25th, 2026 6:00 am
Real Parkinson’s Disease Hope from Jupiter Neurosciences - Aug 19th, 2026 10:32 am
Anavex Urges Shareholders to Back Six Director Nominees Ahead of 2026 Annual Meeting - Aug 17th, 2026 9:04 am
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees - Aug 17th, 2026 6:00 am
Anavex Life Sciences Faces September Board Vote as Blarcamesine Regulatory Strategy Advances - Aug 11th, 2026 9:13 am
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders - Aug 11th, 2026 6:00 am
Anavex Announces Board Refresh as It Seeks to Strengthen Governance and Advance Drug Pipeline - Aug 3rd, 2026 8:09 am